|Bid||16.10 x 400|
|Ask||16.11 x 8800|
|Day's range||15.98 - 16.78|
|52-week range||8.31 - 24.43|
|PE ratio (TTM)||2.37|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.75|
Mar.08 -- Safkhet Capital Founder and Chief Investment Office Fahmi Quadir discusses her short position on Valeant and the state of the pharmaceutical industry. She speaks with Bloomberg's Vonnie Quinn on "Bloomberg Markets."
NEW YORK, March 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Valeant Pharmaceuticals International (VRX) closed higher on Monday, helped by news of its $1.25 billion debt offering, maturing in 2026. Valeant has been on a wild ride lately, seeing its market value triple since bottoming in April 2016. Late last month the specialty-pharma giant lost ground after earnings, but it’s hard to ignore the balance sheet, as Valeant has been trying to shrink the large debt load it took on following an acquisition spree under previous management.
Valeant Pharmaceuticals International Inc. plans to kill a $29.8 million stock award it gave Chief Executive Officer Joseph Papa as the company revamps its compensation program for senior managers.
Safkhet Capital Founder and Chief Investment Office Fahmi Quadir discusses her short position on Valeant and the state of the pharmaceutical industry. She speaks with Bloomberg's Vonnie Quinn on "Bloomberg ...
Chinese conglomerate Sanpower Group is not concerned by trade tensions between the U.S. and China. The company, which acquired a Valeant subsidiary for $820 million last summer, is still in talks for future ...
After a topsy-turvy day that saw the market rise, then fall, then rise again, the S&P 500 advanced 0.3%, to 2728.12, while the Dow Jones Industrial Average ticked up 9.36 points, or 0.04%, to 24,884.12. The SPDR S&P 500ETF (SPY) has dropped 1%, to $270.30, at 5:42 p.m. on the news, while the SPDR Dow Jones Industrial Average ETF (DIA) has slumped 1%, to $246.10. —Ben Levisohn It’s never a dull moment with Valeant Pharmaceuticals International (VRX), the once high-flying pharma company that became the poster child for pharmaceutical excess.
Valeant (VRX) announced disappointing results in the fourth quarter. The outlook for 2018 was dismal too, which disappointed investors.
Are you confused about the impact of potential tariffs on the market? Remember, the Dow dropped 420 points last Thursday as tariffs first were seen as a real threat, but the benchmark rallied back from early protectionist-related losses on Friday as the market baked away the edge. RBC's Lori Calvasina writes that the down-and-up reaction from the market is a sign that "the jury's still out" on whether the tariffs actually go through.
Valeant is taking an "overly sanguine" long-term view of its business, an analyst said after the firm offered a mixed fourth-quarter report.
Just ask Valeant Pharmaceuticals International (VRX), who joined specialty pharmaceutical companies Endo Pharmaceuticals (ENDP) and Perrigo (PRGO), who released their results yesterday, as earnings losers. Heading into this morning's fourth-quarter earnings release, the beaten-down specialty pharmaceutical company had seen its market value triple since bottoming in April 2016. Valeant reported a profit of 98 cents a share--analysts had expected 96 cents a share--on revenue of $2.16 billion, just below forecasts for $2.2 billion.
Valeant Pharmaceuticals International Inc. told investors Wednesday that new products will be a key part of the drugmaker’s turnaround strategy. Just don’t ask for too many details on the numbers.
The Laval, Quebec-based company said it had profit of $1.45 per share. Earnings, adjusted for non-recurring gains, were 98 cents per share. The results did not meet Wall Street expectations. The average ...
Valeant Pharmaceuticals International Inc.’s CEO said in late 2016 that he saw running the drugmaker as the “turnaround opportunity of a lifetime.” That’s not what Wednesday’s quarterly results suggest....
Valeant Pharmaceuticals International Inc. shares fell 3.5% in premarket trade Wednesday after the company reported a fourth-quarter revenue miss and downbeat 2018 guidance. Earnings for the latest quarter ...
Valeant Pharmaceuticals International Inc. announced that it had secured a licensing agreement for a potential psoriasis drug Tuesday afternoon, just hours before the company is scheduled to announce quarterly ...
Valeant Pharmaceuticals International (VRX) will report earnings on Wednesday morning, which could be a chance for the pharmaceutical company to turn around its year-to-date losing streak. Analysts are looking for Valeant to earn 97 cents a share in the quarter, down from $1.04 in the third quarter and $1.26 in the fourth-quarter of 2016. The stock has certainly been volatile lately--its down 9.5% in 2018--hit by downgrades that indicate that there's still plenty of skepticism, about the once high-flying specialty pharma company.